Not medical advice. A record of published research and our assessments of it. The limits

GLP-1 receptor agonist treatment reduces the risk of developing dementia.

Current status: ContradictoryEvidence weakening · Dementia
Why: Large observational cohorts in type 2 diabetes and a meta-analysis of RCT secondary outcomes suggest lower dementia incidence, but confounding by indication and healthy-user effects are plausible. The two phase 3 evoke trials found no slowing of progression in established early Alzheimer's disease, and ELAD (liraglutide) missed its primary endpoint. Prevention in cognitively normal people has not been tested in a randomized trial.
What would change it: A randomized prevention trial with incident dementia or validated cognitive decline as the primary outcome.

Observational replication using active comparators with negative-control outcomes and without diabetes as an entry requirement.
Linked studies: 6 · 4 supports · 1 contradicts · 1 mixed
Last updated: Sep 13, 2026

The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.

01The evidence

The evidence, sorted by what it shows

GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related DementiasRetrospective cohort · 2025 · Study tier 3 · Different population · Benefit
Target-trial emulation in T2D: ADRD HR 0.67 vs other glucose-lowering drugs; no difference vs SGLT2i.
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-AnalysisMeta-analysis · 2025 · Study tier 3 · Different population · Benefit
Meta-analysis of RCTs: GLP-1RAs OR 0.55 for dementia (secondary/adverse-event outcomes, few events); overall class result null.
Mapping the effectiveness and risks of GLP-1 receptor agonistsRetrospective cohort · 2025 · Study tier 3 · Different population · Mixed
VA atlas: reduced neurocognitive disorders vs usual care; observational.
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the USRetrospective cohort · 2024 · Study tier 4 · Different population · Benefit
EHR emulation in T2D: semaglutide associated with 40-70% lower first AD diagnosis; short 3-year window; diagnosis-code outcome.

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trialsRandomized trial · 2026 · Study tier 1 · Partial match · Null · Industry funded
evoke/evoke+: no effect on CDR-SB at 104 weeks in 3808 people with early AD; trials discontinued for lack of efficacy.

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trialRandomized trial · 2026 · Study tier 3 · Partial match · Mixed · Partly industry funded
ELAD phase 2b: primary endpoint (cerebral glucose metabolism) null; executive-function secondary nominally better.

02History